Urinary Tract Cancer Treatment Guided by CDKN1A and RB1 Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bladder cancer lack effective targeted therapies, particularly for patients with specific genetic mutations, and there is a need for better predictive biomarkers to determine chemotherapy responsiveness.
Innovation Solution
A method involving the identification of loss-of-function mutations in CDKN1A and RB1 genes, combined with the use of checkpoint kinase inhibitors and DNA damaging agents, to treat urinary tract cancers, including bladder cancer, based on genetic profiling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used for bladder cancer patients, then treatment can be provided to all patients, but treatment effectiveness is poor with only 22% five-year survival rate for late-stage kidney cancer and limited responsiveness prediction for bladder cancer
Solution Approach 1:
The patent performs genetic profiling of CDKN1A and RB1 mutations before initiating chemotherapy treatment. This preliminary action identifies patients with loss-of-function mutations who are predicted to have enhanced sensitivity to cisplatin-based therapies, allowing clinicians to select appropriate patients for intensive chemotherapy regimens before treatment begins, thereby improving treatment effectiveness while avoiding unnecessary complexity for patients unlikely to respond
Solution Approach 2:
The patent applies different treatment strategies based on the specific genetic profile of individual patients. Patients with loss-of-function mutations in both CDKN1A and RB1 receive intensified cisplatin-based chemotherapy, while patients without these mutations receive alternative or reduced-intensity treatments. This localized customization of treatment quality based on genetic characteristics resolves the contradiction by improving effectiveness for responsive patients without universally increasing treatment complexity
2Measurement precision
If genetic profiling for CDKN1A and RB1 mutations is performed to identify patients for targeted therapy, then treatment precision and responsiveness prediction are improved, but diagnostic complexity and testing requirements increase
Solution Approach 1:
The patent extracts and focuses on detecting only two specific genetic markers (loss-of-function mutations in CDKN1A and RB1 genes) rather than performing comprehensive genomic sequencing. This extraction of essential diagnostic information improves predictive biomarker accuracy for chemotherapy responsiveness while significantly reducing diagnostic complexity and testing requirements compared to whole-genome approaches
Solution Approach 2:
The patent uses next-generation sequencing technology to efficiently detect genetic mutations. This copying approach allows simultaneous analysis of multiple genetic markers from small tissue or blood samples, achieving high measurement precision for predictive biomarkers while keeping the detection process manageable through automated high-throughput sequencing methods
Data Source
AI summary
A method of treating urinary tract cancer in a subject in need thereof is described. The method includes determining if there are loss-of-function mutations in the CDKN1A and RB1 genes in a biological sample from the subject; and treating the subject with a combination of a checkpoint kinase inhibitor and a DNA damaging agent if there are loss-of-function mutations in the CDKN1A and RB1 genes. Alternately, the method includes determining if there is a loss-of-function mutations in a CDKN1A gene in a biological sample from the subject; determining if there is a mutation in a second gene selected from the list consisting of RAB44, TERT, MUC16, HRNR, and FLG; and selecting specific anticancer treatment for the subject based on the identification of a mutation in the second gene.